等待开盘 02-04 09:30:00 美东时间
0.000
0.00%
华盛资讯1月28日讯,新聚思公布2025财年年度业绩,公司年度营收625.08亿美元,同比增长6.9%,归母净利润8.20亿美元,同比增长20.1%。
01-28 08:18
TD SYNNEX posts FY net income of USD 1.32 billion TD SYNNEX reported its financial results for the fiscal year ending November 30, 2025. Revenue was 100% of total sales for the period. Cost of revenue accounted for 93.01% of sales, while gross profit represented 6.99%. Selling, general and administr
01-28 05:04
DLT Solutions Achieves CMMC Level 2 Certification DLT Solutions, LLC, a subsidiary of TD SYNNEX Corporation, has achieved Cybersecurity Maturity Model Certification (CMMC) Level 2. This certification validates DLT’s capability to safeguard Controlled Unclassified Information (CUI) in accordance with
01-27 22:46
TD SYNNEX Extends Trade Receivables Securitization Maturity to 2028 TD SYNNEX Corporation has amended its accounts receivable securitization program by entering into the Seventh Omnibus Amendment to the Fifth Amended and Restated Receivables Funding and Administration Agreement and the Third Amended
01-27 05:07
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据TD SYNNEX业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** - 总账单金额(Gross Billings):243亿美元,同比增长15%,按固定汇率计算增长13%,创公司历史新高 - 净营收(Net Revenue):174亿美元,同比增长10%,超出指导区间高端 **盈利能力:** - 毛利润(Gross Profit):12亿美元,同比增长15% - 毛利率(占总账单比例):5%,与去年同期持平 - Non-GAAP营业收入:4.97亿美元,同比增长18% - Non-GAAP净收入:3.13亿美元 -
01-16 12:30
今日重点评级关注:Needham:维持Cartesian Therapeutics"买入"评级,目标价从40美元升至42美元;Piper Sandler:维持Acrivon Therapeutics"超配"评级,目标价从6美元升至8美元
01-12 14:09
5 analysts have expressed a variety of opinions on TD Synnex (NYSE:SNX) over th...
01-10 03:01
TD SYNNEX Corporation (NYSE:SNX) posted upbeat fourth-quarter results on Thursd...
01-10 01:39
Barrington Research analyst Vincent Colicchio maintains TD Synnex (NYSE:SNX) with a Outperform and maintains $182 price target.
01-09 21:52